Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Deep sequencing of plasma and proviral HIV-1 to establish coreceptor usage: what is the clinical impact of the quasispecies distribution?

Abbate I, Rozera G, Giombini E, D'Offizi G, Nicastri E, Narciso P, Ippolito G, Capobianchi MR.

J Infect Dis. 2011 Sep 15;204(6):971-3; author reply 973-4. doi: 10.1093/infdis/jir427. No abstract available.

PMID:
21849294
2.

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Infect Dis. 2011 Jan 15;203(2):237-45. doi: 10.1093/infdis/jiq030.

3.

HIV-1 coreceptor tropism in India: increasing proportion of X4-tropism in subtype C strains over two decades.

Gupta S, Neogi U, Srinivasa H, Banerjea AC, Shet A.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):397-404. doi: 10.1097/QAI.0000000000000046.

PMID:
24189148
4.

Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.

Abbate I, Rozera G, Tommasi C, Bruselles A, Bartolini B, Chillemi G, Nicastri E, Narciso P, Ippolito G, Capobianchi MR.

Clin Microbiol Infect. 2011 May;17(5):725-31. doi: 10.1111/j.1469-0691.2010.03350.x.

5.

Changes in HIV-1 tropism: clinical and prognostic consequences.

Mosier DE.

Eur J Med Res. 2007 Oct 15;12(9):371-4. No abstract available.

PMID:
17933716
6.

Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.

Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E.

Clin Infect Dis. 2011 Apr 1;52(7):925-8. doi: 10.1093/cid/cir072.

7.

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.

Soulié C, Fourati S, Lambert-Niclot S, Malet I, Wirden M, Tubiana R, Valantin MA, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2010 Apr;65(4):749-51. doi: 10.1093/jac/dkq029.

PMID:
20150182
8.

Geno2pheno[454]: a Web server for the prediction of HIV-1 coreceptor usage from next-generation sequencing data.

Thielen A, Lengauer T.

Intervirology. 2012;55(2):113-7. doi: 10.1159/000332002.

PMID:
22286879
9.

Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA.

Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glascock C, Harrigan PR.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):506-10. doi: 10.1097/QAI.0b013e3181d0558f.

PMID:
20512044
10.

Are the proposed env mutations actually associated with resistance to maraviroc?

Saracino A, Monno L, Brindicci G, Trillo G, Altamura M, Punzi G, Lagioia A, Angarano G.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):550-2. doi: 10.1097/QAI.0b013e3181ba46a6. No abstract available.

PMID:
20220379
11.

Use of a commercial HIV co-receptor tropism assay in clinical practice.

McCarthy MW, Genzen JR, Wilkin TJ, Singh HK.

AIDS Patient Care STDS. 2015 Feb;29(2):53-4. doi: 10.1089/apc.2014.0212. No abstract available.

12.

Current tests to evaluate HIV-1 coreceptor tropism.

Rose JD, Rhea AM, Weber J, Quiñones-Mateu ME.

Curr Opin HIV AIDS. 2009 Mar;4(2):136-42. doi: 10.1097/COH.0b013e328322f973. Review.

PMID:
19339953
13.

HIV-1 tropism.

Iwamoto A, Hosoya N, Kawana-Tachikawa A.

Protein Cell. 2010 Jun;1(6):510-3. doi: 10.1007/s13238-010-0066-2. Review. No abstract available.

14.

The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates.

Lin NH, Negusse DM, Beroukhim R, Giguel F, Lockman S, Essex M, Kuritzkes DR.

J Virol Methods. 2010 Oct;169(1):39-46. doi: 10.1016/j.jviromet.2010.06.012.

15.

Genotypic tests for determining coreceptor usage of HIV-1.

Kuritzkes DR.

J Infect Dis. 2011 Jan 15;203(2):146-8. doi: 10.1093/infdis/jiq034. No abstract available.

16.

Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.

Seclén E, Del Mar González M, De Mendoza C, Soriano V, Poveda E.

J Antimicrob Chemother. 2010 Jul;65(7):1493-6. doi: 10.1093/jac/dkq156.

PMID:
20488982
17.

Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage.

Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, Bruel P, Sandres-Sauné K, Marchou B, Massip P, Izopet J.

J Clin Virol. 2010 Feb;47(2):126-30. doi: 10.1016/j.jcv.2009.11.018.

PMID:
20015684
18.

Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection.

Council OD, Swanson MD, Spagnuolo RA, Wahl A, Garcia JV.

Antimicrob Agents Chemother. 2015 Dec;59(12):7847-51. doi: 10.1128/AAC.01496-15.

19.

Next-generation sequencing to assess HIV tropism.

Swenson LC, Däumer M, Paredes R.

Curr Opin HIV AIDS. 2012 Sep;7(5):478-85. doi: 10.1097/COH.0b013e328356e9da. Review.

PMID:
22832710
20.

Poor performance of bioinformatics programs for genotypic prediction of coreceptor usage of HIV-1 group O isolates.

Rupp D, Geuenich S, Keppler OT.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):412-3. doi: 10.1097/QAI.0b013e3181c9f53f. No abstract available.

PMID:
20190586

Supplemental Content

Support Center